Stockscreener 앱 받기
0.185
0.38%
0.0007
시간 외 거래:
.18
-0.005
-2.70%
전일 마감가:
$0.1843
열려 있는:
$0.1904
하루 거래량:
338.20K
Relative Volume:
0.87
시가총액:
$7.73M
수익:
$20.27M
순이익/손실:
$-63.80M
주가수익비율:
-0.1217
EPS:
-1.52
순현금흐름:
$-68.35M
1주 성능:
+11.18%
1개월 성능:
-15.10%
6개월 성능:
-77.51%
1년 성능:
-85.32%
1일 변동 폭
$0.1803
$0.1926
1주일 범위
$0.1639
$0.20
52주 변동 폭
$0.1417
$1.90
Carisma Therapeutics Inc Stock (CARM) Company Profile
명칭
Carisma Therapeutics Inc
전화
(267) 491-6422
주소
3675 MARKET STREET, PHILADELPHIA
CARM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CARM
Carisma Therapeutics Inc
|
0.185 | 6.95M | 20.27M | -63.80M | -68.35M | -1.52 |
|
ONC
Beigene Ltd Adr
|
241.43 | 27.03B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.00 | 112.64B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 40.86M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
588.34 | 64.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
75.06 | 6.07B | 0 | -153.72M | -103.81M | -2.00 |
Carisma Therapeutics Inc Stock (CARM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-12 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-12-10 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-04-11 | 개시 | BTIG Research | Buy |
| 2023-10-03 | 개시 | CapitalOne | Overweight |
| 2023-07-06 | 개시 | Evercore ISI | Outperform |
| 2023-05-31 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-05-24 | 개시 | H.C. Wainwright | Buy |
| 2023-04-14 | 개시 | Robert W. Baird | Outperform |
모두보기
Carisma Therapeutics Inc 주식(CARM)의 최신 뉴스
Carisma Therapeutics Inc (CARM): An Important Analyst Insights - Stocksregister
Carisma Therapeutics Inc (NASDAQ: CARM) Stock Sentiment: What’s Wall Street Saying? - Stocksregister
Layoff Tracker: Allogene Cuts 28% of Staff to Extend Runway, Focus on Clinical Programs - BioSpace
Carisma Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Carisma Therapeutics, Inc. (NASDAQ:CARM) Given Average Recommendation of “Hold” by Brokerages - Defense World
Financial Metrics Unveiled: Carisma Therapeutics Inc (CARM)’s Key Ratios in the Spotlight - DWinneX
Carisma Therapeutics Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView
Carisma Therapeutics to Present at Upcoming Conferences - Seeking Alpha
Biopharma restructurings reflect strategy of short-term pain for long-term gains - BioWorld MedTech
Carisma Therapeutics, Inc. (NASDAQ:CARM) Given Average Rating of “Hold” by Analysts - Defense World
Sagimet Biosciences (NASDAQ:SGMT) and Carisma Therapeutics (NASDAQ:CARM) Head-To-Head Review - Defense World
Philly weekly roundup: Carisma Therapeutics layoffs; PPA's AI ticketing; HiveBio's first cohort - Technical.ly
Carisma Therapeutics Inc’s Market Journey: Closing Weak at 0.19, Down -0.26 - DWinneX
CARISMA THERAPEUTICS Earnings Preview: Recent $CARM Insider Trading, Hedge Fund Activity, and More - Nasdaq
Carisma Therapeutics Focuses on Strategic Alternatives Amid Revised Operating Plan - MSN
Philly’s Carisma Therapeutics slashed its workforce to 6 from 46 for sale or wind down - MSN
Carisma Therapeutics Full Year 2024 Earnings: Misses Expectations - Yahoo Finance
Carisma Therapeutics (NASDAQ:CARM) Price Target Lowered to $1.00 at D. Boral Capital - Defense World
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Carisma Therapeutics to Present at AASLD 2024 on Liver Fibrosis Treatment - MSN
Carisma winds down operations, lays off 95% of remaining staff - Fierce Biotech
Penn spinout Carisma Therapeutics lays off 84% of its staff, explores possible sale - The Business Journals
Carisma Therapeutics Provides Corporate Updates - Citizen Tribune
Carisma Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Carisma Therapeutics Board Approves Revised Operating Plan; Reduces Workforce - MarketScreener
Carisma Therapeutics Inc. SEC 10-K Report - TradingView
Carisma Therapeutics (CARM) to Release Earnings on Monday - The AM Reporter
Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Business And Shares Still Trailing The Industry - simplywall.st
Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Consensus Rating of “Hold” from Analysts - Defense World
Century Therapeutics, Inc. (IPSC) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annua - GuruFocus.com
Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Consensus Recommendation of “Hold” from Analysts - Defense World
Michael Klichinsky to Speak at H.C. Wainwright Cell Therapy Virtual Conference - MSN
Carisma Therapeutics Announces Upcoming Presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 - Quantisnow
Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - Quantisnow
Carisma Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Conference - MSN
Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference - Quantisnow
Carisma Therapeutics, Inc. (NASDAQ:CARM) Short Interest Update - Defense World
Carisma Therapeutics, Inc. (NASDAQ:CARM) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
Carisma Therapeutics Inc (CARM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
17.27%
1.06%
자본화:
|
볼륨(24시간):